These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 20209622

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K.
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [Abstract] [Full Text] [Related]

  • 5. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M, Florence RR, Pantanowitz L, Visintainer PF, Cibas ES, Otis CN.
    Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB, Ladanyi M, Rusch VW, Zakowski MF.
    Cancer; 2003 Feb 25; 99(1):51-6. PubMed ID: 12589646
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M, Hoogsteden HC, Van der Kwast TH.
    J Pathol; 1991 Oct 25; 165(2):137-43. PubMed ID: 1744800
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
    Attanoos RL, Griffin A, Gibbs AR.
    Histopathology; 2003 Sep 25; 43(3):231-8. PubMed ID: 12940775
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
    Tigrani DY, Weydert JA.
    Am J Clin Pathol; 2007 Apr 25; 127(4):580-4. PubMed ID: 17369133
    [Abstract] [Full Text] [Related]

  • 18. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
    Chang S, Oh MH, Ji SY, Han J, Kim TJ, Eom M, Kwon KY, Ha SY, Choi YD, Lee CH, Lee Y, Jung SH.
    Pathol Int; 2014 Dec 25; 64(12):607-12. PubMed ID: 25376377
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T.
    Diagn Cytopathol; 2011 Jun 25; 39(6):395-401. PubMed ID: 21574259
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.